KOL Perspectives: Perception of mirikizumab in Moderate-to-severe UC
Orbisresearch.com published “Perception of mirikizumab in Moderate-to-severe UC Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, December 07, 2018 ) This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.
Questions topics -
- Perception of Phase II mirikizumab induction data in UC
- Perception of mirikizumab’s Phase III study in UC
- Future expectations of mirikizumab in UC
- Future expectations for mirikizumab in Crohn’s disease
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2392051
Key Highlights:
- All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
- Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab’s ongoing Phase III UC trial
- KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during July 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392051
Key Players:
• Lilly
• Takeda
• Pfizer
• Janssen
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/kol-perspectives-perception-of-mirikizumab-in-moderate-to-severe-uc
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Questions topics -
- Perception of Phase II mirikizumab induction data in UC
- Perception of mirikizumab’s Phase III study in UC
- Future expectations of mirikizumab in UC
- Future expectations for mirikizumab in Crohn’s disease
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2392051
Key Highlights:
- All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
- Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab’s ongoing Phase III UC trial
- KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during July 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392051
Key Players:
• Lilly
• Takeda
• Pfizer
• Janssen
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/kol-perspectives-perception-of-mirikizumab-in-moderate-to-severe-uc
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.